Treatment of CD4+ T cells isolated from RA patients with abatacept was shown to enhance the frequency of IL-10 producing LAG3+ Tregs [11], a potent subtype of Tregs known to produce high levels of IL-10 [12] and IL-35 [13]. Here, LAG3 is linked to rheumatoid arthritis.